Basking Biosciences, Inc. CEO Julia Owens will share updates on Basking’s clinical development progress in acute ischemic stroke, including the Phase 2 RAISE trial of BB-031 and recent Phase 1 results for BB-025.
Published
Signal category
Research & Knowledge
Quote
“Julia will share updates on Basking’s clinical development progress in acute ischemic stroke, including the Phase 2 RAISE trial of BB-031, our investigational targeted, reversible thrombolytic, and recent Phase 1 results for BB-025, its direct-acting reversal agent.”
— Basking Biosciences, Inc. team
Company
Basking Biosciences, Inc.
Redefining the future of thrombosis treatment
- Industry
- Biotechnology
- Location
- Research Triangle, US
- Company size
- 22 employees
Basking Biosciences is a clinical-stage biopharmaceutical company redefining how potentially life-threatening blood clots are treated. Its novel, investigational therapies are designed to significantly improve safety and efficacy, broadening access to many more patients. Its lead program, BB-031, is the first rapid-onset, short-acting thrombolytic therapy with a reversal agent, currently in development for the treatment of acute ischemic stroke (AIS). By inhibiting von Willebrand Factor (vWF), a key driver in clot formation, BB-031 aims to deliver targeted, potent thrombolytic activity that could enable more patients to receive timely, life-saving treatment after stroke.
Founded 2019